Dacarbazine hydrochloride
Based on 16 publication(s) in Google Scholar
Dacarbazine hydrochloride is a cell cycle nonspecific antineoplastic alkylating agent. Dacarbazine hydrochloride inhibits T and B lymphoblastic response, with IC50 values of 50 and 10 μg/mL, respectively. Dacarbazine hydrochloride can be used for the research of metastatic malignant melanoma.
For research use only. We do not sell to patients.
- CAS No.: 17925-90-5
- Formula: C6H11ClN6O
- Molecular Weight:218.64
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Dacarbazine hydrochloride
More- Nature. 2023 Jun;618(7964):374-382. [Abstract]
- Nat Commun. 2024 Sep 10;15(1):7923. [Abstract]
- Adv Sci (Weinh). 2024 Dec;11(48):e2408707. [Abstract]
- Theranostics. 2020 Jul 25;10(21):9477-9494. [Abstract]
- J Nanobiotechnology. 2023 Oct 19;21(1):383. [Abstract]
- Carbohydr Polym. 2024 Dec 15:346:122645. [Abstract]
- Cell Rep Med. 2025 Apr 2:102053. [Abstract]
- Cell Death Dis. 2025 Apr 9;16(1):268. [Abstract]
- Phytother Res. 2024 Jun;38(6):2800-2817. [Abstract]
- J Ginseng Res. 2024 Nov;48(6):559-569. [Abstract]
- J Ethnopharmacol. 2024 Apr 24:324:117759. [Abstract]
- J Mol Med (Berl). 2019 Aug;97(8):1183-1193. [Abstract]
- Heliyon. 2024 Jan 18;10(3):e24988. [Abstract]
- Exp Cell Res. 2020 Aug 1;393(1):112054. [Abstract]
- J Cancer Res Clin Oncol. 2025 Dec 17;152(1):12. [Abstract]
- SSRN. 2024 Mar 20.
-
In Vivo Efficacy Study
-
Cell Proliferation/Viability Assay
-
Cell Proliferation/Viability Assay
-
In Vivo Efficacy Study
-
Histological Imaging/Staining
All Antibiotic Isoforms
More
Biological Activity
Chemical Information
-
CAS No. 17925-90-5
-
Molecular Weight 218.64
-
Formula C6H11ClN6O
-
SMILES
O=C(C1=C(/N=N/N(C)C)NC=N1)N.[H]Cl
-
Synonyms
Imidazole Carboxamide hydrochloride
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (16)
-
Journal Impact Factor
-
Most Recent
-
Nature
2023 Jun;618(7964):374-382. PMID: 37225988
Dacarbazine hydrochloride purchased from MedChemExpress. Usage Cited in: Nature. 2023 Jun;618(7964):374-382. [Abstract]
Dacarbazine (60 mg/kg; i.p.; every other day for 8 d) significantly reduced red blood cell (RBC), reticulocyte (RET), and hemoglobin (HGB) counts in PBS- or B16F10-CL-EVP-educated mice.
-
Nat Commun
2024 Sep 10;15(1):7923. PMID: 39256387 -
Adv Sci (Weinh)
Patient-Derived Melanoma Immune-Tumoroids as a Platform for Precise High throughput Drug Screening. [Abstract]2024 Dec;11(48):e2408707. PMID: 39475010
Dacarbazine hydrochloride purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 Dec;11(48):e2408707. [Abstract]
Dacarbazine (DTIC) (500 µM; 72 h) reduced the diameter and metabolic activity of MCTs except monoculture tumoroids, especially the triples and quadruples, resulting in a decrease of approximately 32% and 28% in relative diameter, respectively, and caused a high number of apoptotic cells to detach from the main structure.
-
Theranostics
Molecular signatures of BRCAness analysis identifies PARP inhibitor Niraparib as a novel targeted therapeutic strategy for soft tissue Sarcomas. [Abstract]2020 Jul 25;10(21):9477-9494. PMID: 32863940 -
J Nanobiotechnology
Combination of ferroptosis and pyroptosis dual induction by triptolide nano-MOFs for immunotherapy of Melanoma. [Abstract]2023 Oct 19;21(1):383. PMID: 37858186
Dacarbazine hydrochloride purchased from MedChemExpress. Usage Cited in: J Nanobiotechnology. 2023 Oct 19;21(1):383. [Abstract]
Dacarbazine (DAC) (5 mg/kg; i.v.; once every three days for 3 times) significantly inhibited the growth of subcutaneous B16F10 melanoma xenografts in C57BL/6 mice.
Dacarbazine hydrochloride purchased from MedChemExpress. Usage Cited in: J Nanobiotechnology. 2023 Oct 19;21(1):383. [Abstract]
H&E staining of tumors in each group at the end of treatment. The results showed that Dacarbazine (DAC) (5 mg/kg; i.v.; once every three days for 3 times) caused significant cell necrosis and nucleopaenia in tumors of B16F10 tumor-bearing mice. Scale bar, 100 μm.
-
Carbohydr Polym
Chitosan/dextran-based organohydrogel delivers EZH2 inhibitor to epigenetically reprogram chemo/immuno-resistance in unresectable metastatic melanoma. [Abstract]2024 Dec 15:346:122645. PMID: 39245506 -
Cell Rep Med
CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. [Abstract]2025 Apr 2:102053. PMID: 40187357 -
Cell Death Dis
MTCH2 regulates NRF2-mediated RRM1 expression to promote melanoma proliferation and dacarbazine insensitivity. [Abstract]2025 Apr 9;16(1):268. PMID: 40204724
Dacarbazine hydrochloride purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2025 Apr 9;16(1):268. [Abstract]
Dacarbazine (20 mg/kg; i.p.; 20 d) reduced tumor growth rates and tumor sizes of melanoma xenograft mice.
-
Phytother Res
Isoalantolactone exerts anti-melanoma effects via inhibiting PI3K/AKT/mTOR and STAT3 signaling in cell and mouse models. [Abstract]2024 Jun;38(6):2800-2817. PMID: 38526171 -
J Ginseng Res
20(S)-Ginsenoside Rh2 induces apoptosis and autophagy in melanoma cells via suppressing Src/STAT3 signaling. [Abstract]2024 Nov;48(6):559-569. PMID: 39583170 -
J Ethnopharmacol
Screening of anti-melanoma compounds from Morus alba L.: Sanggenon C promotes melanoma cell apoptosis by disrupting intracellular Ca2+ homeostasis. [Abstract]2024 Apr 24:324:117759. PMID: 38219884 -
J Mol Med (Berl)
2019 Aug;97(8):1183-1193. PMID: 31201471 -
Heliyon
2024 Jan 18;10(3):e24988. PMID: 38317912 -
Exp Cell Res
Network-based analysis with primary cells reveals drug response landscape of acute myeloid leukemia. [Abstract]2020 Aug 1;393(1):112054. PMID: 32376287 -
J Cancer Res Clin Oncol
Comprehensive analysis based on spatial domains identifies CD44 as a potential target of puerarin. [Abstract]2025 Dec 17;152(1):12. PMID: 41405724 -
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)